Mycology Immunoassays Testing Market

Mycology Immunoassays Testing Market Size and Share Forecast Outlook 2025 to 2035

The Mycology Immunoassays Testing Market is estimated to be valued at USD 5.8 billion in 2025 and is projected to reach USD 9.9 billion by 2035, registering a compound annual growth rate (CAGR) of 5.5% over the forecast period.

Quick Stats for Mycology Immunoassays Testing Market

• Mycology Immunoassays Testing Market Value (2025): USD 5.8 billion
• Mycology Immunoassays Testing Market Forecast Value (2035): USD 9.9 billion
• Mycology Immunoassays Testing Market Forecast CAGR: 5.5%
• Leading Segment in Mycology Immunoassays Testing Market in 2025: ELISA (36.9%)
• Key Growth Regions in Mycology Immunoassays Testing Market: North America, Asia-Pacific, Europe
• Top Key Players in Mycology Immunoassays Testing Market: Abbott Laboratories, Inc., Beckman Coulter, Inc., bioMérieux SA, MiraVista Diagnostics, F. Hoffmann-La Roche Ltd., Siemens AG, Ortho-Clinical Diagnostics, Inc., ELITech Group

Mycology Immunoassays Testing Market Key Takeaways

Metric	Value
Mycology Immunoassays Testing Market Estimated Value in (2025 E)	USD 5.8 billion
Mycology Immunoassays Testing Market Forecast Value in (2035 F)	USD 9.9 billion
Forecast CAGR (2025 to 2035)	5.5%

Why is the Mycology Immunoassays Testing Market Growing?

The Mycology Immunoassays Testing market is witnessing steady growth, driven by the rising prevalence of fungal infections and the increasing demand for rapid and accurate diagnostic solutions. Immunoassays, particularly those based on advanced technologies, provide high sensitivity and specificity, enabling early detection and improved patient outcomes. The market is being supported by advancements in diagnostic platforms, automation, and multiplex testing capabilities that enhance efficiency and reduce turnaround times.

Hospitals, clinical laboratories, and research institutions are increasingly adopting immunoassays to manage patient care, monitor treatment efficacy, and conduct epidemiological studies. Regulatory emphasis on diagnostic accuracy and compliance with laboratory standards further drives adoption. Integration with electronic health records and laboratory information systems enables streamlined workflow and better data management.

Growing awareness among healthcare professionals regarding fungal disease burden, coupled with increasing investment in diagnostic infrastructure, is shaping market growth As demand for precise, rapid, and scalable testing solutions continues to rise, the Mycology Immunoassays Testing market is positioned for sustained expansion over the coming decade.

Segmental Analysis

The mycology immunoassays testing market is segmented by technology, end user, and geographic regions. By technology, mycology immunoassays testing market is divided into ELISA, Rapid Tests, ELISPOT, and Polymerase Chain Reaction (PCR). In terms of end user, mycology immunoassays testing market is classified into Hospitals, Clinical Laboratories, Blood Banks, Research Centers, and Others. Regionally, the mycology immunoassays testing industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the ELISA Technology Segment

The ELISA technology segment is projected to hold 36.9% of the market revenue in 2025, establishing it as the leading technology type. Growth in this segment is being driven by ELISA’s ability to provide high accuracy, reproducibility, and quantitative analysis for a wide range of fungal pathogens. The technology allows for automated, high-throughput testing, which reduces manual errors and improves laboratory efficiency.

ELISA assays are versatile and compatible with multiple sample types, including serum, plasma, and tissue, enabling broad application across clinical diagnostics. Hospitals and laboratories favor ELISA due to its reliability, established protocols, and cost-effectiveness compared with alternative methods.

Ongoing technological enhancements, such as improved antibodies, detection systems, and software integration, are further strengthening adoption As the demand for rapid, sensitive, and scalable testing solutions increases in response to rising fungal infections, ELISA technology is expected to maintain its leadership, supported by continuous innovation and the ability to meet evolving clinical requirements.

Insights into the Hospitals End-User Segment

The hospitals end-user segment is anticipated to account for 41.2% of the market revenue in 2025, making it the leading end-user category. Growth is being driven by the increasing need for accurate fungal diagnostics to manage patient care, particularly in immunocompromised populations. Hospitals leverage immunoassays for early detection, treatment monitoring, and outbreak management, enabling timely clinical decision-making and improving patient outcomes.

Integration of testing platforms with hospital information systems allows efficient data handling, reporting, and clinical workflow optimization. The segment is also supported by increasing investments in diagnostic infrastructure, laboratory automation, and training of healthcare personnel. Hospitals are prioritizing adoption of rapid and reliable immunoassays to reduce hospitalization duration and associated costs.

Rising awareness of fungal infections, regulatory requirements, and the growing burden of complex infections are further reinforcing the preference for advanced immunoassay solutions As healthcare systems continue to focus on quality patient care and operational efficiency, hospitals are expected to remain the largest end-user segment, driving sustained market growth.

Market Overview

Mycology Immunoassays Testing Market Overview

The frequency of invasive fungal infections has dramatically increased in the recent years and has high mortality and morbidity. Accurate and early diagnosis is very important for the appropriate antifungal therapy. Conventional techniques like microbiology, radiological and histological remain the basis of diagnosis but have limited impact on clinical decision making.

There is always a need to characterize fungi accurately and quickly, which can be done by mycology immunoassays test. The fungi are parasitic and saprophytic eukaryotic organisms. The diagnostic methods for fungal infections are direct examination, radiology, and fungal culture and non-culture methods.

Diabetic patients are more susceptible to infectious diseases such as Cryptococcus, mucocutaneous candidosis and dematiaceous fungal infection. Rapid and accurate diagnosis of these life threatening fungal diseases is of clinical importance. Mycology is concerned with the study of the fungi. Histopathology, microscopy and use of fungal-specific stains plays an important role in the diagnosis of infections.

Fungi cause disease in man by virtue of their allergenicity, toxigenicity or pathogenicity. Mycology immunoassays are used to detect products or host responses to infection.

Analysis of Mycology Immunoassays Testing Market By Key Countries

Country	CAGR
China	7.4%
India	6.9%
Germany	6.3%
Brazil	5.8%
USA	5.2%
UK	4.7%
Japan	4.1%

Country-wise Analysis

The Mycology Immunoassays Testing Market is expected to register a CAGR of 5.5% during the forecast period, exhibiting varied country level momentum. China leads with the highest CAGR of 7.4%, followed by India at 6.9%. Developed markets such as Germany, France, and the UK continue to expand steadily, while the USA is likely to grow at consistent rates. Japan posts the lowest CAGR at 4.1%, yet still underscores a broadly positive trajectory for the global Mycology Immunoassays Testing Market. In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 6.3%. The USA Mycology Immunoassays Testing Market is estimated to be valued at USD 2.2 billion in 2025 and is anticipated to reach a valuation of USD 2.2 billion by 2035. Sales are projected to rise at a CAGR of 0.0% over the forecast period between 2025 and 2035. While Japan and South Korea markets are estimated to be valued at USD 302.9 million and USD 163.5 million respectively in 2025.

Key Players in the Mycology Immunoassays Testing Market

• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• bioMérieux SA
• MiraVista Diagnostics
• F. Hoffmann-La Roche Ltd.
• Siemens AG
• Ortho-Clinical Diagnostics, Inc.
• ELITech Group

Scope of the Report

Item	Value
Quantitative Units	USD 5.8 Billion
Technology	ELISA, Rapid Tests, ELISPOT, and Polymerase Chain Reaction (PCR)
End User	Hospitals, Clinical Laboratories, Blood Banks, Research Centers, and Others
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Covered	United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa
Key Companies Profiled	Abbott Laboratories, Inc., Beckman Coulter, Inc., bioMérieux SA, MiraVista Diagnostics, F. Hoffmann-La Roche Ltd., Siemens AG, Ortho-Clinical Diagnostics, Inc., and ELITech Group

Mycology Immunoassays Testing Market by Segments

Technology:

• ELISA
• Rapid Tests
• ELISPOT
• Polymerase Chain Reaction (PCR)

End User:

• Hospitals
• Clinical Laboratories
• Blood Banks
• Research Centers
• Others

Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa